Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Nov;96(47):e8733.
doi: 10.1097/MD.0000000000008733.

Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date

Cheng Chen  1 , Senlin Yin, Shizhen Zhang, Mengmeng Wang, Yu Hu, Peizhi Zhou, Shu Jiang
Affiliations
Case Reports

Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date

Cheng Chen et al. Medicine (Baltimore). 2017 Nov.

Abstract

Rationale: Aggressive pituitary adenomas and pituitary carcinomas are rare and demand multiple treatment strategies. Temozolomide, an orally active alkylating chemotherapeutic agent, has recently been recommended as a salvage medication for refractory pituitary adenomas or carcinomas.

Patient concerns: A 17-year-old male presenting with aggressive prolactinoma that continued to progress despite surgery, gamma knife, and dopamine agonists.

Diagnoses: The diagnosis of refractory aggressive prolactinoma was made on the basis of clinical findings and the lack of efficacy of conventional treatment.

Interventions: The patient received the most frequently recommended regimen of temozolomide treatment for 22 cycles.

Outcomes: Temozolomide resulted in a remarkable shrinkage of tumor mass and inhibition of prolactin secretion and this patient's clinical condition improved progressively.

Lessons: Temozolomide can be used as a salvage treatment to refractory pituitary tumors and o(6)-methylguanine-DNA methyltransferase (MGMT) status is a significant predictor to the effectiveness of temozolomide based on the existing literature.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
(A) Contrast-enhanced coronal T-1 weighted MRI showed a sellar and suprasellar tumor. (B) Residual tumor 5 months after gamma knife therapy. (C) Sagittal image showed the apparent shrinkage of tumor and the decompressed of optic nerve 7 months after the initiation of cabergoline. (D) Regrowth of tumor mass 26 months after cabergoline. (E) Preoperative MRI demonstrated a 3.5 cm × 3.1 cm × 3.7 cm tumor mass compressing pituitary stalk and optic chiasma. (F) MRI indicated a residual tumor 5 months after operation. (G) MRI indicated that the residual tumor expanded again after second course of gamma knife. (H) Sellar tumor remarkable reduction with cystic degeneration after 22 months of temozolomide treatment.
Figure 2
Figure 2
Graph showing the serum Prolactin concentration [ng/ml] at approximately 1-month interval. Prolactin dropped rapidly after the commencement of temozolomide.
See this image and copyright information in PMC

References

    1. Daly AF, Tichomirowa MA, Beckers A. The epidemiology and genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 2009;23:543–54. - PubMed
    1. Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neurooncology 2012;14(Suppl 5):v1–49. - PMC - PubMed
    1. Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA 2017;317:516–24. - PubMed
    1. Di Ieva A, Rotondo F, Syro LV, et al. Aggressive pituitary adenomas: diagnosis and emerging treatments. Nat Rev Endocrinol 2014;10:423–35. - PubMed
    1. Chatzellis E, Alexandraki KI, Androulakis II, et al. Aggressive pituitary tumors. Neuroendocrinology 2015;101:87–104. - PubMed

Publication types